The New Multi Capsule “Medspresso Torro” Gets Unleashed

The New Multi Capsule “Medspresso Torro” Gets Unleashed

CAPE TOWN, SA / ACCESSWIRE / November 4, 2021 / WUHAN GENERAL GROUP, INC. (OTC PINK:WUHN) (“WGG” or the “Company”), a bioceutical company focused on alternative plant-based cannabinoids and mental health therapeutic research is pleased to share the following update:

Medspresso™ is pleased to announce the launch of the new Medspresso™ Torro Dual Purpose Home Espresso Maker. The new design is unique in that it’s one of very few capsule systems that accommodate both Dolcé Gusto® and Nespresso® size capsules. The machine is a welcome addition to the existing Medspresso product range.

The Torro is available immediately for purchase on the Medspresso website and will roll into preferred retailers across South Africa just in time for the festive season. In addition to the South African market, there are plans for export to international online retailers like Amazon UK, US, and DE. Other exciting markets that are being considered are the Middle East, South America, the Far East, and Australasia.

CEO and Founder of M2Bio™ Jeff Robinson explains: “We are very excited for the launch of this amazing delivery system. The South African capsule market has massive potential for growth and this offering will give consumers the choice of preferred capsule and beverage in the comfort of their homes. There are already 75 different capsule beverages available in both Dolcé Gusto® and Nespresso® size capsules to choose from and this machine can accommodate both, opening up a new world of coffee for consumers. Capsule coffee and beverages have come a long way since Nespresso® launched their systems, the new paradigm shift is towards sustainability, capsule biodegradability, and recycling. Nespresso® has a great recycling program for consumers and our Medspresso™ range is proudly fully biodegradable, our consumers can enjoy their favorite coffees with a clear conscience.”

The powerful Torro machine features a 19-Bar pressure pump, serving up a coffee in as little as 25 seconds, and users can choose between a small or large cup. The machine comes with easily programmable functions, bringing a personalized barista-style coffee experience into your home. The drip tray is adjustable in height to suit everything from tiny espresso cups to taller mugs. It’s small, streamlined, and sleek-looking too. It looks smart on any kitchen worktop or office space without taking up too much roo

Grab your machine now.

About Wuhan General Group, Inc./ M2Bio Sciences, Inc

Wuhan General Group, Inc. (DBA M2bio Sciences), through its wholly-owned subsidiary MJ MedTech is a nutraceutical biotechnology company focused on alternative plant-based cannabinoids and psilocybin medical research that develops and commercializes a range of CBD and mushrooms-based products under Dr. AnnaRx™, Medspresso™, and Liviana™ brands. In addition, our research and clinical trials with psilocybin are aimed at new therapies that will help patients who suffer from alcohol addiction, mental illness, and cardiovascular diseases. Our mission is to advance botanical-based medicine to the forefront by deploying best-practice science and medicine, clinical research, and emerging technologies. The Company is traded on the Over-the-Counter Bulletin Board of NASDAQ under the trading symbol “WUHN”.

Publicly traded company (OTC Pink: WUHN)
Follow us on Twitter:
Follow us on Facebook:
Follow us on YouTube:
Follow us on Instagram:

Forward-Looking Statements:

Safe Harbour Statement – In addition to historical information, this press release may contain statements that constitute forward-looking statements within the meaning of the Securities Act of 1933 and the Securities Exchange Act of 1934, as amended by the Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this press release include the intent, belief, or expectations of the Company and members of its management team with respect to the Company’s future business operations and the assumptions upon which such statements are based. Prospective investors are cautioned that any such forward-looking statements are not guarantees of future performance, and involve risks and uncertainties and that actual results may differ materially from those contemplated by such forward-looking statements. Factors that could cause these differences include, but are not limited to, failure to complete anticipated sales under negotiations, lack of revenue growth, client discontinuances, failure to realize improvements in performance, efficiency and profitability, and adverse developments with respect to litigation or increased litigation costs, the operation or performance of the Company’s business units or the market price of its common stock. Additional factors that could cause actual results to differ materially from those contemplated within this press release can also be found on the Company’s website. The Company disclaims any responsibility to update any forward-looking statements.

SOURCE: Wuhan General Group, Inc./ M2Bio Sciences, Inc.


View source version on